CEBPA and acute myeloid leukemia: In turn, mutation in replication factor CCAAT/enhancer-banding protein α (CEBPA) is associated with good response to therapy.6, 7 With current karyotyping methods, no chromosomal abnormality is found in 40% to 50% of AML patients, and differentiation between different prognostic subtypes in this group of patients by present approaches to molecular genetics seems to be of great importance.4, 8, 9 The majority of these cases are characterized as “AML not otherwise characterized” by the WHO categorization.10